LSA
AXSM icon

Lion Street Advisors’s Axsome Therapeutics AXSM Stock Holding History

Lion Street Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$565K Buy
14,677
+5,619
+62% +$633K 0.2% 101
2025
Q2 		$946K Sell
9,058
-489
-5% -$51.8K 0.29% 80
2025
Q1 		$1.11M Sell
9,547
-52
-0.5% -$5.92K 0.35% 60
2024
Q4 		$812K Buy
9,599
+1,344
+16% +$124K 0.26% 86
2024
Q3 		$742K Sell
8,255
-60
-0.7% -$5.24K 0.26% 84
2024
Q2 		$669K Sell
8,315
-3,617
-30% -$268K 0.25% 88
2024
Q1 		$950K Hold
11,932
– – 0.39% 51
2023
Q4 		$950K Sell
11,932
-2,350
-16% -$157K 0.39% 51
2023
Q3 		$998K Sell
14,282
-620
-4% -$46.3K 0.33% 59
2023
Q2 		$574K Sell
14,902
-230
-2% -$17K 0.19% 99
2023
Q1 		$933K Buy
15,132
+1,955
+15% +$128K 0.29% 59
2022
Q4 		$507K Sell
13,177
-135
-1% -$8.07K 0.27% 61
2022
Q3 		$590K Buy
13,312
+135
+1% +$6.75K 0.29% 45
2022
Q2 		$513K Buy
13,177
+75
+0.6% +$2.37K 0.27% 60
2022
Q1 		$538K Sell
13,102
-75
-0.6% -$2.33K 0.28% 57
2021
Q4 		$503K Hold
13,177
– – 0.25% 64
2021
Q3 		$433K Buy
+13,177
New +$514K 0.23% 70

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Lion Street Advisors's AXSM Position: Q3 2025 in Review

Lion Street Advisors increased its Axsome Therapeutics (AXSM) stake by 62% in Q3 2025, buying an estimated $633K and bringing the position to 14,677 shares worth $565K. The position accounts for 0.2% of the portfolio, ranked #101.

Lion Street Advisors first reported a position in AXSM in Q3 2021 and has held it in 17 quarters since. The position peaked at $1.11M in Q1 2025. 355 funds tracked by Wall St. Rank hold AXSM as of Q3 2025.

  • Lion Street Advisors held 14,677 shares of Axsome Therapeutics worth $565K as of Q3 2025.
  • Lion Street Advisors bought 5,619 Axsome Therapeutics shares in Q3 2025, an estimated $633K.
  • Axsome Therapeutics made up 0.2% of Lion Street Advisors's portfolio in Q3 2025, its #101 holding.
  • Lion Street Advisors first reported a position in Axsome Therapeutics in Q3 2021 and has held it in 17 quarters since.
  • Lion Street Advisors's Axsome Therapeutics position peaked at $1.11M in Q1 2025.
  • 355 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2025.

Based on Lion Street Advisors's 13F filing for Q3 2025, filed 10 Nov 2025.